- Home
- FTLF vs CRDF Comparison
FTLF vs CRDF Comparison
Compare FTLF & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTLF
- CRDF
- Stock Information
- Founded
- FTLF 2005
- CRDF 1999
- Country
- FTLF United States
- CRDF United States
- Employees
- FTLF N/A
- CRDF N/A
- Industry
- FTLF Medicinal Chemicals and Botanical Products
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FTLF Health Care
- CRDF Health Care
- Exchange
- FTLF Nasdaq
- CRDF Nasdaq
- Market Cap
- FTLF 149.3M
- CRDF 169.6M
- IPO Year
- FTLF N/A
- CRDF N/A
- Fundamental
- Price
- FTLF $13.61
- CRDF $2.98
- Analyst Decision
- FTLF Strong Buy
- CRDF Strong Buy
- Analyst Count
- FTLF 2
- CRDF 4
- Target Price
- FTLF $20.50
- CRDF $12.25
- AVG Volume (30 Days)
- FTLF 9.8K
- CRDF 1.2M
- Earning Date
- FTLF 08-13-2025
- CRDF 08-07-2025
- Dividend Yield
- FTLF N/A
- CRDF N/A
- EPS Growth
- FTLF 22.19
- CRDF N/A
- EPS
- FTLF 0.90
- CRDF N/A
- Revenue
- FTLF $63,856,000.00
- CRDF $587,000.00
- Revenue This Year
- FTLF $4.72
- CRDF N/A
- Revenue Next Year
- FTLF $6.61
- CRDF N/A
- P/E Ratio
- FTLF $15.14
- CRDF N/A
- Revenue Growth
- FTLF 9.13
- CRDF N/A
- 52 Week Low
- FTLF $9.83
- CRDF $2.01
- 52 Week High
- FTLF $17.75
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- FTLF 43.17
- CRDF 41.74
- Support Level
- FTLF $13.66
- CRDF $2.98
- Resistance Level
- FTLF $14.54
- CRDF $3.99
- Average True Range (ATR)
- FTLF 0.56
- CRDF 0.29
- MACD
- FTLF -0.11
- CRDF -0.08
- Stochastic Oscillator
- FTLF 20.11
- CRDF 5.34
About FTLF FitLife Brands Inc.
FitLife Brands Inc is a provider of proprietary nutritional supplements for health-conscious consumers. The company markets and sells its products under NDS, PMD, Siren labs, Core active, Metis nutrition, Isatori, and Biogenetic laboratories brand names. Its product portfolio consists of sports nutrition, energy, sports drink products, meal replacement products, and weight loss products. The firm derives its revenue from product sales. Its product categories include Natural & Organic Foods, Functional Foods, Natural & Organic Personal Care and Household Products, and Supplements.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.